AOD 9604 dosing schedule female protocols are not FDA-approved. See typical research amounts, timing, cycle length, and safety notes for women.
Anyone searching for an AOD 9604 dosing schedule for women is working without an official answer: AOD-9604 is not FDA-approved for human use in the United States, and no regulator has published a recommended dose for women or men. The protocols discussed most often land between 250 mcg and 300 mcg per day, usually split into two injections and cycled roughly five days on and two days off for eight to twelve weeks. Those numbers come from early research and community self-experimentation rather than a validated clinical guideline, so they should be treated as reference points, not instructions.
Is There an Official AOD-9604 Dose for Women?
No. There is no approved, evidence-based AOD-9604 dose for women. AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176–191) that was studied years ago for weight management, but it never earned approval for human use.
The early human studies used different doses, delivery methods, and patient populations than the subcutaneous protocols circulating today, and they did not report enough female-specific data to set a standard. Women have historically been underrepresented in early metabolic research, which is one reason online dosing advice for women is largely extrapolated from male self-reports.
Typical AOD-9604 Dosing Schedules Discussed for Women
Even though no schedule is validated, a handful of patterns appear repeatedly in forums, vendor guides, and community write-ups. The table below summarizes the most common ones.
| Protocol style | Daily amount | How it's split | Cycle pattern | Why people choose it |
|---|---|---|---|---|
| Standard split dose | 300 mcg | 150 mcg twice daily | 5 days on, 2 days off | Most frequently cited starting point |
| Single daily dose | 250–300 mcg | One injection | Daily or 5-on/2-off | Simpler routine, fewer injections |
| Conservative | 200–250 mcg | One or two injections | 5-on/2-off, 8 weeks | Common for first-time users |
| Higher dose | 300–500 mcg | Split into two | 4–12 weeks | Not supported by human data; higher side-effect risk |
No trial has compared these schedules head to head in women, so the differences between them are largely theoretical. Cycles are usually 8 to 12 weeks long, followed by a break of 4 to 8 weeks.
Timing: Morning Fasted or Before Bed?
AOD-9604 is often described as a peptide that does not raise blood sugar or trigger appetite, because it targets the fat-metabolizing portion of growth hormone rather than the growth-promoting portion. That description comes from animal and laboratory work, not from modern clinical trials.
Most protocols place the injection in the morning, 20 to 30 minutes before the first meal, while others dose before bed. Consistency matters more than the exact clock time. The most common answer to how often do you take aod 9604 is once or twice a day, five days a week.
How to Reconstitute AOD-9604 Without Gelling
Learning how to reconstitute aod 9604 properly prevents most of the problems people report, including the cloudy, gelatinous clumping that makes a vial unusable. AOD-9604 is a fragile peptide, and rough handling breaks it down.
- Let the vial and the bacteriostatic water sit at room temperature for 15–20 minutes.
- Swab both stoppers with an alcohol pad and let them dry.
- Draw the water and aim the stream at the glass wall, not directly at the powder.
- Add the water slowly, then roll the vial gently between your palms. Never shake it.
- Refrigerate at 2–8°C, protect it from light, and avoid repeated freeze–thaw cycles.
If you run into aod-9604 gelling up, the usual causes are water sprayed straight onto the powder, shaking, warm storage, or a vial that has already degraded. A gelled vial cannot be dosed accurately, so it is safer to discard it than to guess at the concentration.
Do AOD-9604 Reviews Support the Results People Claim?
Most of the aod 9604 reviews found on forums, YouTube, and vendor blogs are anecdotal. Users rarely track diet, training, or body composition with enough rigor to attribute changes to the peptide.
Published trial results for AOD-9604 did not show clinically meaningful fat loss compared with placebo, which is a major reason the compound was never approved. Anyone reporting dramatic results is likely also in a calorie deficit, training consistently, or using additional compounds.
Can You Combine AOD-9604 With Tirzepatide?
There is no research on using aod 9604 with tirzepatide, and the combination is untested in humans. Tirzepatide is an FDA-approved prescription drug, while AOD-9604 is a research chemical sold with a “not for human consumption” label.
Stacking them raises several practical concerns:
- Overlapping side effects such as nausea, fatigue, and injection-site reactions.
- No way to tell which compound is driving results or causing problems.
- Unknown interactions involving fat metabolism and blood sugar regulation.
Anyone using tirzepatide should discuss additional peptides with the prescriber managing that prescription instead of adding them independently. The same caution applies to other research compounds sometimes mentioned alongside AOD-9604, such as MOTS-c.
Safety, Sourcing, and Legal Status
In the United States, AOD-9604 is not an approved drug and is not a lawful dietary supplement ingredient. It is sold as a research chemical for laboratory use only, which means there is no guarantee of purity, sterility, or accurate labeling.
Commonly reported side effects are mild and include redness or soreness at the injection site and occasional headache. Long-term safety data in women do not exist. People who are pregnant, breastfeeding, or managing a hormone-sensitive condition should avoid it, and anyone with a medical history should talk with a healthcare professional first.
When evaluating a supplier, look for a batch-specific certificate of analysis, third-party purity testing, and sterile manufacturing documentation. Price alone is not a reliable indicator of quality.
The Bottom Line on AOD-9604 Dosing for Women
There is no official, evidence-based AOD-9604 dose for women, and the schedules circulating online are community conventions rather than clinical standards. AOD-9604 lacks FDA approval and modern human data, and it has not been shown to produce meaningful fat loss on its own.
If you decide to explore it, responsible steps include discussing it with a clinician, following accurate reconstitution and storage practices, and avoiding combinations with prescription drugs without medical oversight.
Frequently Asked Questions
What is a typical AOD 9604 dosage for women?
No official AOD 9604 dose exists for women because the peptide is not FDA-approved for human use. The amount discussed most often in community protocols is 250 to 300 mcg per day, frequently split into two 150 mcg injections and cycled five days on and two days off for eight to twelve weeks. These figures come from early research and self-reporting, not from a validated clinical guideline.
How often do you take AOD 9604?
Most protocols call for one or two injections per day, taken five days a week with two days off. Some users dose daily and then take a longer break of four to eight weeks between cycles. No human trial has established an optimal dosing frequency for this peptide.
Can you take AOD 9604 with tirzepatide?
There is no research on combining AOD-9604 with tirzepatide, and the pairing is untested in humans. Combining a research chemical with a prescription GLP-1 drug can compound side effects such as nausea, fatigue, and injection-site reactions. Anyone using tirzepatide should clear any additional peptide with the prescriber managing that prescription first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.